Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Evotec AG : Notification and public disclosure of transactions by persons

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/18/2017 | 02:15pm CEST


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

18.09.2017 / 14:12
The issuer is solely responsible for the content of this announcement.


1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Title: Dr.
First name: Werner
Last name(s): Lanthaler

2. Reason for the notification

a) Position / status
Position: Member of the managing body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
Evotec AG

b) LEI
529900F9KI6OYITO9B12 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: DE0005664809

b) Nature of the transaction
Purchase of shares by exercising stock options
Transaction linked to the exercise of share option programmes

c) Price(s) and volume(s)
Price(s) Volume(s)
17.7711 EUR 1064577.75 EUR

d) Aggregated information
Price Aggregated volume
17.7711 EUR 1064577.75 EUR

e) Date of the transaction
2017-09-15; UTC+2

f) Place of the transaction
Outside a trading venue



18.09.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Internet: www.evotec.com

 
End of News DGAP News Service

37751  18.09.2017 


© EQS 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC AG
07/09EVOTEC : confirm closing of transaction with Sanofi to accelerate infectious dis..
AQ
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
07/03EVOTEC AG : Evotec Confirm Closing Of Transaction With Sanofi To Accelerate Infe..
AC
07/03EVOTEC : Confirm closing of transaction with sanofi to accelerate infectious dis..
EQ
06/28EVOTEC : achieves second milestone in diabetes alliance with Sanofi
AQ
06/25EVOTEC AG : Evotec Achieves Second Milestone in Diabetes Alliance With Sanofi
AC
06/25EVOTEC : Resolutions of the Annual General Meeting 2018 of Evotec AG
AQ
06/25EVOTEC : Achieves second milestone in diabetes alliance with sanofi
EQ
06/21EVOTEC : and Sanofi sign definitive agreement to combat infectious diseases
AQ
06/20EVOTEC AG : Resolutions of the Annual General Meeting 2018 of Evotec AG
AC
More news
News from SeekingAlpha
05/31Evotec forms LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research .. 
05/21Celgene teams up with Evotec to discover new cancer treatments 
05/09Evotec's (EVOTF) CEO Werner Lanthaler on Q1 2018 Results - Earnings Call Tran.. 
05/09Evotec AG 2018 Q1 - Results - Earnings Call Slides 
05/09Evotec AG reports Q1 results 
Financials (€)
Sales 2018 353 M
EBIT 2018 48,4 M
Net income 2018 34,2 M
Debt 2018 70,3 M
Yield 2018 -
P/E ratio 2018 67,77
P/E ratio 2019 47,68
EV / Sales 2018 6,85x
EV / Sales 2019 6,29x
Capitalization 2 350 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 19,9 €
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG17.96%2 745
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
LONZA GROUP9.72%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147